AlphaTON Capital Receives Nasdaq Congratulations for Groundbreaking Cancer Research Tokenization Initiative
AlphaTON Capital (NASDAQ: ATON) announced Nasdaq publicly congratulated the company for pioneering a blockchain-based cancer research tokenization initiative; the recognition was displayed on the Nasdaq Tower in Times Square on October 10, 2025. AlphaTON is partnering with Cyncado Therapeutics to fund oncology programs via tokenized assets, aiming to increase liquidity, improve transparency of fund allocation, lower investor minimums, and accelerate R&D timelines. The company said the model helped advance multiple research programs and that it plans to expand tokenization to more therapeutic areas and institutional partners.
AlphaTON Capital (NASDAQ: ATON) ha annunciato che Nasdaq ha pubblicamente elogiato l'azienda per aver aperto la strada a una iniziativa di tokenizzazione della ricerca sul cancro basata su blockchain; il riconoscimento è stato esposto sulla Nasdaq Tower a Times Square il 10 ottobre 2025. AlphaTON sta collaborando con Cyncado Therapeutics per finanziare programmi oncologici tramite asset tokenizzati, con l'obiettivo di aumentare la liquidità, migliorare la trasparenza dell'allocazione dei fondi, abbassare i minimi d'investimento e accelerare le tempistiche di R&D. L'azienda ha detto che il modello ha contribuito ad avanzare molteplici programmi di ricerca e che intende espandere la tokenizzazione ad altre aree terapeutiche e a partner istituzionali.
AlphaTON Capital (NASDAQ: ATON) anunció que Nasdaq felicitó públicamente a la empresa por innovar en una iniciativa de tokenización de la investigación contra el cáncer basada en blockchain; el reconocimiento se mostró en la Nasdaq Tower en Times Square el 10 de octubre de 2025. AlphaTON se está asociando con Cyncado Therapeutics para financiar programas oncológicos mediante activos tokenizados, con el objetivo de aumentar la liquidez, mejorar la transparencia de la asignación de fondos, disminuir los mínimos de inversión y acelerar los plazos de I+D. La compañía dijo que el modelo ayudó a avanzar varios programas de investigación y que planea ampliar la tokenización a más áreas terapéuticas y a socios institucionales.
AlphaTON Capital (NASDAQ: ATON)은 나스닥이 블록체인 기반의 암 연구 토큰화 이니셔티브를 개척한 회사를 공개적으로 축하했다고 발표했습니다; 이 인정은 2025년 10월 10일에 타임스퀘어의 나스닥 타워에 표시되었습니다. AlphaTON은 Cyncado Therapeutics와 협력하여 토큰화 자산을 통해 종양학 프로그램에 자금을 제공하고, 유동성 증가, 자금 배분의 투명성 향상, 투자자 최소 한도 인하, R&D 일정 가속화를 목표로 합니다. 회사는 이 모델이 여러 연구 프로그램의 진전에 도움이 되었으며 더 많은 치료 영역과 기관 파트너로 토큰화를 확장할 계획이라고 말했습니다.
AlphaTON Capital (NASDAQ: ATON) a annoncé que Nasdaq a publiquement félicité l'entreprise pour avoir ouvert la voie à une initiative de tokenisation de la recherche sur le cancer basée sur la blockchain; la reconnaissance a été affichée sur la Nasdaq Tower à Times Square le 10 octobre 2025. AlphaTON s'associe à Cyncado Therapeutics pour financer des programmes d'oncologie via des actifs tokenisés, dans le but d'accroître la liquidité, d'améliorer la transparence de l'allocation des fonds, de réduire les seuils d'investissement et d'accélérer les délais de R&D. L'entreprise a déclaré que le modèle avait aidé à faire progresser plusieurs programmes de recherche et qu'elle prévoit d'étendre la tokenisation à d'autres domaines thérapeutiques et à des partenaires institutionnels.
AlphaTON Capital (NASDAQ: ATON) kündigte an, dass Nasdaq das Unternehmen öffentlich dafür lobte, eine blockchain-basierte Tokenisierung der Krebsforschung -Initiative voranzutreiben; die Anerkennung wurde am 10. Oktober 2025 am Nasdaq Tower in Times Square angezeigt. AlphaTON geht eine Partnerschaft mit Cyncado Therapeutics ein, um Onkologie-Programme über tokenisierte Vermögenswerte zu finanzieren, mit dem Ziel, Liquidität zu erhöhen, Transparenz der Mittelverteilung zu verbessern, Mindestinvestitionen zu senken und die F&E-Zeiten zu beschleunigen. Das Unternehmen sagte, das Modell habe geholfen, mehrere Forschungsprogramme voranzutreiben, und es plane, die Tokenisierung auf weitere therapeutische Bereiche und institutionelle Partner auszuweiten.
AlphaTON Capital (NASDAQ: ATON) أعلن أن Nasdaq هنّأ الشركة علنًا لكونها رائدة في مبادرة ترميز أبحاث السرطان باستخدام البلوكشين؛ وقد أُظهر التقدير على برج Nasdaq في تايمز سكوير في 10 أكتوبر 2025. تتعاون AlphaTON مع Cyncado Therapeutics لتمويل برامج الأورام عبر أصول مُرمّزة، بهدف زيادة السيولة، وتحسين الشفافية في تخصيص الأموال، وخفض الحد الأدنى للاستثمار، وتسريع جداول البحث والتطوير. قالت الشركة إن النموذج ساعد في تقدم عدة برامج بحثية وتخطط لتوسيع الترميز إلى مزيد من المناطق العلاجية وشركاء مؤسسيين.
AlphaTON Capital (NASDAQ: ATON) 宣布纳斯达克公开祝贺公司在区块链基础上的癌症研究代币化倡议；这一认可以及在2025年10月10日在时代广场的纳斯达克大厦展示。AlphaTON正在与Cyncado Therapeutics合作，通过代币化资产为肿瘤治疗计划提供资金，目标是增加流动性、提升资金分配透明度、降低投资门槛，并加速研发时间表。公司表示，该模式已帮助推进多项研究计划，并计划将代币化扩展到更多治疗领域和机构合作伙伴。
- None.
- None.
Insights
Nasdaq recognition highlights institutional visibility, but material impact depends on execution and regulatory clarity.
AlphaTON Capital secured a public congratulation from Nasdaq and a Times Square display on
The business mechanism claims to convert research funding into tradable digital tokens to enhance liquidity, traceability, and lower participation thresholds using blockchain. These features can change capital access only if token structures, custody, and secondary-market mechanics meet regulatory and institutional standards.
Key dependencies and risks include legal/regulatory approval for tokenized medical-research assets, custodial and compliance arrangements, and market demand for the tokens. Monitor public regulatory filings, announced custody partners, and any stated trading venues; also watch for additional partner disclosures and rollout details.
The collaboration frames a new funding route for cancer programs, yet disclosed facts lack financial terms or clinical milestones.
AlphaTON and Cyncado Therapeutics describe tokenization as a means to direct capital toward oncology programs, claiming progress on multiple research projects previously constrained by funding limits. The stated outcome is faster access to capital for R&D rather than any disclosed clinical or financial results.
Risks include reliance on the token model to attract meaningful capital without diluting research focus and the need to demonstrate transparent fund allocation on-chain. Track concrete metrics such as announced funding amounts, specific program milestones, and named institutional participants to assess whether the initiative moves from publicity to measurable support for clinical development.
New York, NY, Oct. 10, 2025 (GLOBE NEWSWIRE) --
AlphaTON Capital (NASDAQ: ATON), a specialized digital asset treasury company focused on developing the TON and Telegram ecosystem, and new pioneer in blockchain-based healthcare financing, today announced that Nasdaq has publicly congratulated the company on its innovative approach to funding cancer research through asset tokenization. The recognition was displayed prominently on the iconic Nasdaq Tower in Times Square, marking a significant milestone in the convergence of digital assets and medical research funding.
Transforming Cancer Treatment Through Tokenization
AlphaTON Capital's partnership with Cyncado Therapeutics represents a revolutionary approach to financing life-saving cancer research. By leveraging blockchain technology and asset tokenization, the company has created a transparent, accessible investment mechanism that connects global investors directly with promising oncology research programs.
"This recognition from Nasdaq validates our vision of democratizing access to healthcare innovation investments," said Brittany Kaiser, Chief Executive Officer of AlphaTON Capital. "Traditional pharmaceutical research funding has been limited to institutional investors and venture capital firms. Through tokenization, we're opening these opportunities to a broader supporter base while accelerating the path from laboratory discoveries to patient treatments."
A New Model for Medical Research Funding
The AlphaTON-Cyncado collaboration addresses critical challenges in cancer research funding:
- Enhanced Liquidity: Tokenized assets provide greater flexibility and market access
- Transparent Allocation: Blockchain technology ensures clear tracking of fund deployment
- Reduced Barriers: Lower minimum financial participation enables broader audience participation in medical innovation
- Accelerated Timelines: Streamlined capital access speeds up research and development cycles
Impact on Cancer Treatment Development
Cyncado Therapeutics, the beneficiary of this innovative funding approach, is developing next-generation cancer treatments targeting previously undruggable tumor pathways. The partnership has already enabled the advancement of multiple research programs that were previously constrained by traditional funding limitations.
"AlphaTON's exploration of co-developing this tokenization initiative with us has fundamentally changed how we approach research capitalization," stated Peter Malloy, CEO of Cyncado Therapeutics. "This funding model allows us to focus on science rather than spending years in funding roadshows."
Market Recognition and Future Outlook
The Nasdaq Tower feature represents more than ceremonial recognition—it signals growing institutional acceptance of tokenized assets in regulated markets. AlphaTON Capital's success in navigating complex regulatory frameworks while maintaining innovation has positioned the company as a leader in the emerging institutional digital asset space.
AlphaTON Capital in partnership with its subsidiary Cyncado Therapeutics plans to expand its tokenization initiative to additional therapeutic areas and research institutions, with several partnerships currently in development.
About AlphaTON Capital Corp
AlphaTON Capital is a specialized digital asset treasury company focused on building and managing a strategic reserve of TON tokens and developing the Telegram ecosystem. The Company implements a comprehensive treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, AlphaTON Capital provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram's billion user platform while maintaining the governance standards and reporting transparency of a Nasdaq listed company. Led by Chief Executive Officer Brittany Kaiser, the Company's activities span network validation and staking operations, development of Telegram-based applications, and strategic investments in TON-based decentralized finance protocols, gaming platforms, and business applications. AlphaTON Capital Corp is incorporated in the British Virgin Islands and trades on Nasdaq under the ticker symbol “ATON”. AlphaTON Capital, through its legacy business, is also advancing potentially first-in-class therapies that target known checkpoint resistance pathways to potentially achieve durable treatment response and improve quality of life for patients. AlphaTON Capital actively engages in the drug development process and provides strategic counsel to guide development of novel immunotherapy assets and asset combinations.
About Cyncado Therapeutics
Tarus Therapeutics, LLC (dba Cyncado Therapeutics), a clinical stage, wholly owned subsidiary of AlphaTON Capital Corp, is developing potentially best-in-class small molecule adenosine receptor antagonists targeting A2A and A2B receptors to overcome immune suppression in oncology. The Company's lead program, TT-4, is an oral, ultra-selective A2B receptor antagonist with an initial focus on mesothelioma, advancing toward first-patient dosing in Q1 2026. Cyncado is also developing dual-antagonist strategies designed to achieve comprehensive blockade of adenosine-mediated immune evasion, potentially unlocking synergistic anti-tumor effects and durable patient responses.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements other than statements of historical fact, including statements regarding the Company's business strategy, plans and objectives, future operations, exploration of tokenization frameworks, clinical development timelines, potential DeSci applications, TON ecosystem growth, therapeutic development outcomes, regulatory approvals, financing activities, and statements preceded by, followed by, or including words such as "believe," "expects," "anticipates," "intends," "estimates," "will," "may," "plans," "potential," "targets," or similar expressions, are forward-looking statements.
These forward-looking statements are subject to substantial risks and uncertainties, including but not limited to: risks that tokenization or DeSci frameworks may not be pursued or successfully implemented; uncertainty regarding the Company’s and Cyncado’s ability to enter into definitive agreements on reasonable terms; uncertainty regarding clinical trial outcomes and regulatory approvals; uncertainty of the Company's investment in TON and digital assets; regulatory and legal risks associated with digital assets and tokenization; risks related to Telegram's platform and the TON ecosystem; market volatility; competitive risks in both digital assets and therapeutics development; ability to attract and retain key personnel; the Company’s ability to satisfy its debt service obligations and covenant compliance; macroeconomic conditions; and other factors described in "Item 3 – Key Information-Risk Factors" in the Company's Annual Report on Form 20-F for the year ended March 31, 2025, and subsequent reports filed with the Securities and Exchange Commission.
Although the Company believes the expectations reflected in these forward-looking statements are reasonable, actual results may differ materially. The Company undertakes no obligation to update publicly or revise any forward-looking statements, except as required by law.
Contact Information
Investor Relations:
AlphaTON Capital Corp
AlphaTON@icrinc.com
(203) 682-8200
Media Inquiries:
Richard Laermer
RLM PR
AlphaTON@rlmpr.com
(212) 741-5106 X 216
AlphaTON (at) icrinc.com AlphaTON (at) rlmpr.com
FAQ
What did AlphaTON Capital (ATON) announce on October 10, 2025 regarding Nasdaq recognition?
How does AlphaTON's tokenization model with Cyncado Therapeutics affect investor access to oncology funding (ATON)?
Which therapeutic focus did AlphaTON and Cyncado target in the ATON tokenization initiative?
Will AlphaTON (ATON) expand its tokenization program beyond cancer research?
What practical benefits did AlphaTON cite from tokenizing research funding for ATON investors?
